Provided By GlobeNewswire
Last update: Feb 18, 2025
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosuppressants and are off steroids as of the latest follow-up –
Read more at globenewswire.com1.87
-0.04 (-2.09%)
Find more stocks in the Stock Screener
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.